



BELEAVE SIGNS MEMO OF UNDERSTANDING WITH RYERSON UNIVERSITY REGARDING DRUG STANDARDIZATION RESEARCH

Toronto, ON – March 2nd, 2016 - Beleave Inc. (CSE: BE) is pleased to announce that its wholly-owned subsidiary First Access Medical Inc. ("FAM") has signed a memo of understanding (MOU) with Ryerson University to enter into a collaborative drug standardization research project, with the goal of developing high-quality medicinal marijuana extracts. Dr. Lesley Campbell, assistant professor in the Ryerson department of Chemistry and Biology, will be acting as lead investigator for the study.

"We feel that this collaboration will make a valuable contribution to scientific research related to marijuana plant extracts, thus providing physicians in Canada with a greater level of confidence when clinically evaluating their efficacy for the treatment of disease," commented Beleave CEO Dr. Roger Ferriera.

Lesley Campbell of Ryerson's Department of Chemistry & Biology says the marijuana industry could benefit from the wider use of science-based experiments for understanding current and developing pharmaceutical therapies.

"This is an exceptional opportunity to start to understand the influence of a growing environment on the production of active ingredients in Cannabis and will be an important complement to clinical and pharmaceutical research", she said.

The work carried out at Ryerson includes evaluating the most effective and cost efficient methods for plant extract production, adding to Beleave's intellectual property portfolio, and allowing rapid commercialization of products suitable for large-scale development.

Under this agreement, Beleave will provide support for an on-going research partnership and the development of testing facilities. The university and the company have also applied to NSERC matching programs to fund further research and development projects in the future.

About Ryerson

Ryerson University is Canada's leader in innovative, career-oriented education. Urban, culturally diverse and inclusive, the university is home to more than 41,500 students, including 2,400 master's and PhD students, 3,200 faculty and staff, and nearly 170,000 alumni worldwide. For more information, visit www.ryerson.ca

About Beleave

Beleave Inc. (formerly Stream Ventures Inc.) is a biotech company committed to becoming a licensed producer under the *Marihuana for Medical Purposes Regulations* (the "MMPR"). Beleave's wholly owned subsidiary First Access Medical Inc. ("FAM") has applied for a licence to cultivate and sell medical marihuana pursuant to the MMPR. As of the date hereof, FAM has successfully advanced past the security clearance stage and is currently in the review stage of the licensing process. Beleave's purpose built facility is located near Hamilton, Ontario.



Forward-Looking Statements

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Corporation believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Corporation can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the completion of the MMPR licensing process and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Corporation's disclosure documents, which can be found under the Corporation's profile on www.sedar.com.

CONTACT INFORMATION

Beleave Inc.

www.beleave.com

Sebastian de Kloet

+1-905-979-5173

Sebastian@beleave.com